ChromaCode and Protean to launch assay for lung cancer in US
ChromaCode has entered into a partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.
Related Articles
Medtech SMEs seek clearer legislation for device classification
Speakers emphasised the need for classification and approval of devices, and effective licencing and quality control at BioTrinity 2024.
How is prostate cancer detected? #prostatecancer #cancerscreening
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Labcorp launches blood test for neurodegenerative diseases detection
Global life sciences company Labcorp has announced the first commercially available GFAP blood biomarker test in the US.
Telehealth clinical trial cuts hospital cardiac readmissions by 76%
The TELE-ACS designed to test SHL Telemedicine’s SmartHeart system was also able to significant drop emergency hospital visits by 41%.
Boston Scientific initiates study for PFA catheter system
The NAVIGATE-PF study will enrol 30 subjects across Europe with paroxysmal or persistent atrial fibrillation (AF).
Aventa Genomics introduces NGS test for solid tumours
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
CardioPrecision demonstrates new robotic cardiac surgery technique
The robotic surgery platform is aimed at speeding up aortic valve replacement surgeries whilst cutting down on staff.
Medtronic exits “unprofitable” ventilator market
Current North America and Europe market leader drops ventilator product lines, pivots to form Acute Care and Monitoring business.
Insulet touts results from Omnipod 5 trial in type 1 diabetes patients
The automated closed loop system delivered improved glycaemic and patient-reported outcomes versus traditional tech.
How 5G is changing the medical device landscape
Medical devices in Industry 4.0 are providing healthcare providers with greater amounts of data for more accurate diagnostics, but can fourth-generation connectivity keep up?
